ShernanGHoltanMD- Allogeneic HCT/ Cell Therapy(She/Her)

PubMed

• Amphiregulin, ST2,and REG3α Biomarker Risk Algorithms as Predictors of Non-Relapse Mortality in Patients with Acute GVHD.
  Aaron M Etra, Najla El Jurdi, Nikolaos Katsivelos, Deukwoo Kwon, Stephanie C Gergoudis, George Morales, Nikolaos Spyrou, Steven Kowalyk, Paibel Aguayo-Hiraldo, Yu Akah...> ;Blood Advances. 2024 Apr 19
• Long- and short-term effects of fecal microbiota transplantation on antibiotic resistance genes: results from a randomized placebo-controlled trial.
  Armin Rashidi, Maryam Ebadi, Tauseef Ur Rehman, Heba Elhusseini, David Kazadi, Hossam Halaweish, Mohammad H Khan, Andrea Hoeschen, Qing Cao, Xianghua Luo, Amanda J Kab...> ;Gut Microbes. 2024 Mar 13
• Treatment-Sensitive and Treatment-Dependent Chronic Graft-versus-Host Disease Yield Superior Failure-Free and Overall Survival Compared to Treatment-Resistant Chronic ...
  Shannon Herzog, Ryan Shanley, Shernan G Holtan, Margaret L MacMillan, Daniel J Weisdorf, Najla El Jurdi> ;Transplantation and Cellular Therapy. 2024 Mar 11
• The development and flux of the University of Minnesota Survivorship Program: progress, challenges, and opportunities.
  Tara J Rick, Jill Lee, Sasha Skendzel, Kaia Verich, Ashley Schempp, Char Napurski, Holly Kreuser, Lucie Turcotte, Shernan Holtan, Karim Sadak, Anne Blaes> ;Journal of Cancer Survivorship. 2024 Feb 1
• The best GVHD prophylaxis: Or at least progress towards finding it.
  El Jurdi, N., Weisdorf, D., Holtan, S.> ;Best Practice & Research. Clinical Haematology. 2023 Dec 1
• 3 citations
  Potential of Fecal Microbiota Transplantation to Prevent Acute GVHD: Analysis from a Phase II Trial.
  Armin Rashidi, Maryam Ebadi, Tauseef Ur Rehman, Heba Elhusseini, David Kazadi, Hossam Halaweish, Mohammad H Khan, Andrea Hoeschen, Qing Cao, Xianghua Luo, Amanda J Kab...> ;Clinical Cancer Research. 2023 Dec 1
• 1 citations
  Amphiregulin as monitoring biomarker for life-threatening acute graft-versushost disease: secondary analysis of two prospective clinical trials.
  Shernan G Holtan, Najla El Jurdi, Armin Rashidi, Brian C Betts, Connor Demorest, John P Galvin, Margaret L MacMillan, Daniel J Weisdorf, Angela Panoskaltsis-Mortari, M...> ;Haematologica. 2023 Sep 14
• 1 citations
  Temporal variation in oral microbiome composition of patients undergoing autologous hematopoietic cell transplantation with keratinocyte growth factor.
  Bruno Bohn, Miroslava Chalupova, Christopher Staley, Shernan Holtan, Joseph Maakaron, Veronika Bachanova, Najla El Jurdi> ;BMC Microbiology. 2023 Sep 13
• 1 citations
  Pre-transplant and longitudinal changes in faecal microbiome characteristics are associated with subsequent development of chronic graft-versus-host disease.
  Najla El Jurdi, Shernan G Holtan, Andrea Hoeschen, Jessica Velguth, Benjamin Hillmann, Brian C Betts, Margaret L MacMillan, Daniel J Weisdorf, Alexander Khoruts, Armin...> ;British Journal of Haematology. 2023 Oct 1
• 46 citations
  Post-Transplantation Cyclophosphamide-Based Graft-versus-Host Disease Prophylaxis.
  Javier Bolaños-Meade, Mehdi Hamadani, Juan Wu, Monzr M Al Malki, Michael J Martens, Lyndsey Runaas, Hany Elmariah, Andrew R Rezvani, Mahasweta Gooptu, Karilyn T Larkin...> ;The New England Journal of Medicine. 2023 Jun 22
• 3 citations
  Phase II Study of Myeloablative 7-8/8-Matched Allotransplantation with Post-Transplantation Cyclophosphamide, Tacrolimus, and Mycophenolate Mofetil.
  Najla El Jurdi, Alex Hoover, Daniel O'Leary, Qing Cao, Ashish Gupta, Christen Ebens, Joseph E Maakaron, Brian C Betts, Armin Rashidi, Mark B Juckett, Troy Lund, Veroni...> ;Transplantation and Cellular Therapy. 2023 Sep 1
• 2 citations
  Phase II, Open-Label Clinical Trial of Urinary-Derived Human Chorionic Gonadotropin/Epidermal Growth Factor for Life-Threatening Acute Graft-versus-Host Disease.
  Shernan G Holtan, Andrea Hoeschen, Qing Cao, Celalettin Ustun, Brian C Betts, Najla El Jurdi, Joseph Maakaron, Armin Rashidi, Jeffrey S Miller, John E Wagner, Bruce R ...> ;Transplantation and Cellular Therapy. 2023 Aug 1
• 3 citations
  Randomized Double-Blind Phase II Trial of Fecal Microbiota Transplantation Versus Placebo in Allogeneic Hematopoietic Cell Transplantation and AML.
  Armin Rashidi, Maryam Ebadi, Tauseef Ur Rehman, Heba Elhusseini, David Kazadi, Hossam Halaweish, Mohammad H Khan, Andrea Hoeschen, Qing Cao, Xianghua Luo, Amanda J Kab...> ;Journal of Clinical Oncology. 2023 Dec 1
• 2 citations
  A prospective phase 2 clinical trial of a C5a complement inhibitor for acute GVHD with lower GI tract involvement.
  Rohtesh S Mehta, Haris Ali, Yang Dai, Bert Yao, Bethany Overman, Voravit Ratanatharathorn, Saar Gill, Gerard Socié, Kevin Anderson, Jean Yves Cahn, Arshad Mujeebuddin,...> ;Bone Marrow Transplantation. 2023 Sep 1
• 2 citations
  Chronic GVHD after steroid-sensitive, -dependent, and -refractory acute GVHD: incidence and clinical outcomes.
  Shannon Herzog, Daniel J Weisdorf, Ryan Shanley, Ahmad Rayes, Shernan G Holtan, Margaret L MacMillan, Najla El Jurdi, Young, J. H., Jo-Anne Young> ;Blood Advances. 2023 Jul 25
• 2 citations
  Phase II Study of Myeloablative 8/8- or 7/8-Matched Allotransplantation with Post-Transplant Cyclophosphamide, Tacrolimus, and Mycophenolate Mofetil: Marked Reduction ...
  Najla El Jurdi, Alex Hoover, Daniel O'Leary, Qing Cao, Ashish Gupta, Christen Ebens, Joseph Maakaron, Brian C Betts, Armin Rashidi, Mark Juckett, Troy Lund, Veronika B...> ;Medrxiv. 2023 Mar 29
• 1 citations
  Patient-Reported Outcomes in Long-Term Survivors of Autologous Hematopoietic Cell Transplantation in Multiple Myeloma.
  Rajshekhar Chakraborty, Jean Yi, Lisa Rybicki, Jaime Preussler, Abhinav Deol, Alison Loren, Bipin Savani, Heather S L Jim, Jan Cerny, Jana Reynolds, Jennifer Whitten, ...> ;Transplantation and Cellular Therapy. 2023 Jun 1
• 3 citations
  Sarcopenia Predicts Inferior Progression-Free Survival in Lymphoma Patients Treated with Autologous Hematopoietic Stem Cell Transplantation.
  Nuttavut Sumransub, Qing Cao, Mark Juckett, Brian Betts, Shernan Holtan, Najla El Jurdi, Marie Hu, Jeremy Allred, Rita Assi, Joseph E Maakaron> ;Transplantation and Cellular Therapy. 2023 Apr 1
• 5 citations
  Human Effectors of Acute and Chronic GVHD Overexpress CD83 and Predict Mortality.
  Shernan G Holtan, Constanza Savid-Frontera, Kelly Walton, Anne A Eaton, Connor Demorest, Andrea Hoeschen, Ling Zhang, Kayla Reid, Tony Kurian, Zena Sayegh, Estefania J...> ;Clinical Cancer Research. 2023 Mar 14
• 1 citations
  Graft-versus-host disease: teaching old drugs new tricks at less cost.
  Shatha Farhan, Shernan G Holtan> ;Frontiers in Immunology. 2023 Jan 1
• Health-Related Quality of Life Outcomes in Older Hematopoietic Cell Transplantation Survivors.
  Sanghee Hong, Jing Zhao, Shu Wang, Han Wang, Ji-Hyun Lee, Nosha Farhadfar, Joseph P McGuirk, Bipin N Savani, Hashmi K Shahrukh, Patrick Stiff, Nandita Khera, Theresa H...> ;Transplantation and Cellular Therapy. 2023 Mar 1
• Correction to: Disease progression, treatments, hospitalization, and clinical outcomes in acute GVHD: a multicenter chart review.
  Shernan G Holtan, Jingbo Yu, Hannah K Choe, Dilan Paranagama, Jackson Tang, Ahmad Naim, John Galvin, H Joachim Deeg> ;Bone Marrow Transplantation. 2023 Feb 1
• 4 citations
  Bringing Patient and Caregivers Voices to the Clinical Trial Chorus: A Report From the BMT CTN Patient and Caregiver Advocacy Task Force.
  Sumithira Vasu, Shernan G Holtan, Akiko Shimamura, Todd Burnworth, Shauna Whisenton, Sanderson Adams, Brandon Nuechterlein, Nicole Mortier, Jackie Foster, Nancy DiFron...> ;Transplantation and Cellular Therapy. 2023 Jan 1
• Adult Hematology/Oncology Patient Perspectives on Telemedicine Highlight Areas of Focus for Future Hybrid Care Models.
  Alexander A Boucher, Patricia I Jewett, Shernan G Holtan, Bruce R Lindgren, Jane Y C Hui, Anne H Blaes> ;Telemedicine Journal and e-Health. 2023 May 1
• 5 citations
  Fecal β-glucuronidase activity differs between hematopoietic cell and kidney transplantation and a possible mechanism for disparate dose requirements.
  Mohammad Haneef Khan, Guillaume C Onyeaghala, Armin Rashidi, Shernan G Holtan, Alexander Khoruts, Ajay Israni, Pamala A Jacobson, Christopher Staley> ;Gut Microbes. 2022 Aug 3
• Join now to see all

Journal Articles

• Amphiregulin in Intestinal Acute Graft-Versus-Host Disease: A Possible Diagnostic and Prognostic Aid  
  Brittney Schultz, Bruce R Blazar, Daniel J Weisdorf, Shernan G Holtan, Alexander Khoruts, Armin Rashidi, Margaret L MacMillan, Khalid Amin, Byron P Vaughn, Nature
• Phase I Trial of ALT-803, a Novel Recombinant Interleukin-15 Complex, in Patients with Advanced Solid Tumors  
  Jeffrey S Miller, Shernan G Holtan, Sylvia M Lee, Chihiro Morishima, Ann W Silk, Clinical Cancer Research
• Immunomodulatory Effects of Sex Hormones: Requirements for Pregnancy and Relevance in Melanoma  
  Enninga EAL, Holtan SG, Creedon DJ, Dronca RS, Nevala WK, Ognjanovic S, Markovic SN, Mayo Clinic Proceedings, 1/1/2014
• Impact of lymphocyte and monocyte recovery on the outcomes of allogeneic hematopoietic SCT with fludarabine and melphalan conditioning  
  DeCook L, Thoma M, Huneke T, Johnson N, Wiegand R, Patnaik M, Litzow M, Hogan W, Porrata L, Holtan SG, Bone Marrow Transplant, 1/1/2013
• Peripheral blood lymphocyte and monocyte recovery and survival in acute leukemia postmyeloablative allogeneic hematopoietic stem cell transplant  
  Thoma MD, Huneke TJ, DeCook LJ, Johnson ND, Wiegand RA, Litzow MR, Hogan WJ, Porrata LF, Holtan SG, Biology of Blood and Marrow Transplantation, 1/1/2012
• Gemcitabine and Irinotecan as First-Line Therapy for Carcinoma of Unknown Primary: Results of a Multicenter Phase II Trial  
  Holtan SG, Steen PD, Foster NR, Erlichman C, Medeiros F, Ames MM, Safgren SL, Graham DL, Behrens RJ, Goetz MP, PloS one, 1/1/2012
•  
  Holtan SG, O'Connor HM, Fredericksen ZS, Liebow M, Thompson CA, Macon WR, Micallef IN, Wang AH, Slager SL, Habermann TM, International Journal of Cancer, 1/1/2012
• Graft vs GIST?  
  Holtan SG, Palmer S, Okuno S, Hogan W, Bone Marrow Transplant, 1/1/2012
• Regional immunity in melanoma: immunosuppressive changes precede nodal metastasis  
  Mansfield AS, Holtan SG, Grotz TE, Allred JB, Jakub JW, Erickson LA, Markovic SN, Modern Pathology, 1/1/2011
• Expansion of CD16-negative natural killer cells in the peripheral blood of patients with metastatic melanoma  
  Holtan SG, Creedon DJ, Thompson MA, Nevala WK, Markovic SN, Clinical and Developmental Immunology, 1/1/2011
• An organ system based approach to prognosis in advanced melanoma  
  Holtan SG, Mansfield A, Creedon D, Nevala W, Haluska P, Leontovich A, Markovic S, Frontiers in bioscience (Elite edition), 1/1/2011
• Mother knows best: lessons from fetomaternal tolerance applied to cancer immunity  
  Holtan SG, Creedon D, Frontiers in bioscience (Scholar edition), 1/1/2011
• WHO-defined ‘myelodysplastic syndrome with isolated del (5q)’in 88 consecutive patients: survival data, leukemic transformation rates and prevalence of JAK2, MPL and I...  
  Patnaik M, Lasho T, Finke C, Gangat N, Caramazza D, Holtan SG, Pardanani A, Knudson R, Ketterling R, Chen D, Leukemia, 1/1/2010
• Host immunity affects survival in myelodysplastic syndromes: Independent prognostic value of the absolute lymphocyte count  
  Jacobs NL, Holtan SG, Porrata LF, Markovic SN, Tefferi A, Steensma DP, American journal of hematology, 1/1/2010
• Constrictive Pericarditis Due to Graft-vs-Host Disease  
  Holtan SG, Spittell PC, Mayo Clinic Proceedings, 1/1/2010
• Cancer and pregnancy: parallels in growth, invasion, and immune modulation and implications for cancer therapeutic agents  
  Holtan SG, Creedon DJ, Haluska P, Markovic SN, Mayo Clinic Proceedings, 1/1/2009
• Primary myelofibrosis is the most frequent myeloproliferative neoplasm associated with del (5q): clinicopathologic comparison of del (5q)-positive and-negative cases  
  Santana-Davila R, Tefferi A, Holtan SG, Ketterling RP, Dewald GW, Knudson RA, Steensma DP, Chen D, Hoyer JD, Hanson CA, Leuk Res, 1/1/2008
• Myelodysplastic syndromes associated with interstitial deletion of chromosome 5q: Clinicopathologic correlations and new insights from the prelenalidomide era  
  American journal of hematology, 1/1/2008
•  
  Holtan SG, Porrata LF, Colgan JP, Zent CS, Habermann TM, Markovic SN, American journal of hematology, 1/1/2008
• AMD3100 Affects Autograft Lymphocyte Collection and Progression-Free Survival After Autologous Stem Cell Transplantion in Non-Hodgkin Lymphoma  
  Holtan SG, Porrata LF, Micallef IN, Padley DJ, Inwards DJ, Ansell SA, Johnston PB, Gastineau DA, Markovic SN, Clinical Lymphoma, Myeloma & Leukemia, 1/1/2007
• Knowing too much  
  Holtan SG, Journal of Cancer Education, 1/1/2007
• Diagnosis of obesity by primary care physicians and impact on obesity management  
  Bardia A, Holtan SG, Slezak JM, Thompson WG, Mayo Clinic Proceedings, 1/1/2007
•  
  Rao RD, Holtan SG, Ingle JN, Croghan GA, Kottschade LA, Creagan ET, Kaur JS, Pitot HC, Markovic SN, Cancer, 1/1/2006
•  
  Holtan SG, Porrata LF, Inwards DJ, Ansell SM, Micallef IN, Johnston PB, Litzow MR, Gastineau DA, Markovic SN, Br J Haematol, 1/1/2006
•  
  Holtan SG, Knox S, Tefferi A, Journal of Thrombosis and Haemostasis, 1/1/2006
• Join now to see all

Abstracts/Posters

• Obesity-Induced Microbiome Alterations Result in Severe Gastrointestinal Graft-Versus-Host Disease Following Allogeneic Hematopoietic Stem Cell Transplantation
  Shernan Holtan, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/2019
• Outcomes of Chronic Graft-Versus-Host Disease (cGVHD) Following Matched Sibling Donor (MSD) Versus Umbilical Cord Blood Transplant (UCBT)
  Shernan Holtan, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/7/2019
• Chronic Graft-versus-Host Disease Biomarker Discovery and Replication
  Kirk R. Schultz, Amina Kariminia , Sabine Ivison, Holtan, SG., Marie-Josee Hebert , Mary E.D. Flowers, Paul Martin, Jacob Rozmus, Peter Subrt, Barry Storer, Stephanie ..., EBMT, 1/1/2015
• Prognostic Impact of Follistatin in Acute Graft-Versus-Host Disease: Results from BMT CTN 0302 and 0802
  Holtan, SG., Michael R. Verneris, Kirk R Schultz, Laura F. Newell, Gabrielle Meyers, Fiona He, Todd E. DeFor, Margaret L. MacMillan, Biology of Blood and Marrow Transplant, 1/1/2015
• Chronic Graft-versus-Host Disease Biomarker Discovery andReplication: CXCL10 + CXCL9 Provides the Highest Diagnostic Value in Adults
  Amina Kariminia, Holtan, SG., Marie-Josee Hebert, Paul Martin, Stephanie J. Lee, Jan Storek, Stephen Couban, David Szwajcer, Laura Newell, Irwin Walker, Jason Tay, Jo..., CBMTG, 1/1/2015
• Allograft Leukocyte Content and Post-Allogeneic Hematopoietic Cell Transplant Lymphopenia and Monocytopenia
  Thoma M, Glejf J, Jacob EK, Huneke T, DeCook L, Johnson N, Patnaik M, Litzow M, Hogan W, Porrata L, Holtan SG, Biology of Blood and Marrow Transplantation, 1/1/2013
• Chronic GVHD-Associated Serositis and Pericarditis
  Leonard J, Holtan SG, Heitner S, Nonas S, Allen B, Chen AI, Newell LF, Meyers G, Hayes-Lattin B, Gajewski J, Biology of Blood and Marrow Transplantation, 1/1/2013
• Predictive Classification of Chronic GVHD Status by Immune Reconstitution Testing
  Holtan SG, Newell LF, Meyers G, Chen AI, Hayes-Lattin B, Gajewski J, Slater S, Nemecek E, Braziel R, Fan G, Biology of Blood and Marrow Transplantation, 1/1/2013
• Factor Analysis of the Longitudinal Maternal Immune Response to Pregnancy
  Holtan SG, Creedon D, Nevala W, Leontovich A, Markovic S, Journal of Womens Health, 1/1/2013
• Redefining Engraftment Syndrome: The New Mayo Clinic Criteria
  Burnette BL, Holtan SG, Gertz M, Kumar S, Lacy M, Buadi F, Hayman S, Dingli D, Inwards DJ, Johnston PB, Micallef IN, Dispenzieri A, Biology of Blood and Marrow Transplantation, 1/1/2013
• Exhibition of a stem-cell like phenotype with the expression of CD271 in drug-resistant melanoma cells
  Lieser EAT, Leontovich AA, Holtan SG, Nevala WK, Markovic S, Journal of Clinical Oncology, Amer Soc Clinical Oncology, 1/1/2012
• G-CSF Mobilization Alone, a Shorter Duration of Neutropenia, and the Rapidity of Engraftment Are Associated with Engraftment Syndrome in Patients Undergoing Autologous...
  Burnette B, Dispenzieri A, Porrata L, Hogan W, Holtan SG, Biology of Blood and Marrow Transplantation, 1/1/2012
• Impact of Rapid Lymphocyte and Monocyte Recovery on Overall Survival Post-Allogeneic Hematopoietic Stem Cell Transplantation (HSCT) with Fludarabine/Melphalan Conditio...
  DeCook L, Thoma M, Huneke T, Johnson N, Wiegand R, Litzow MR, Hogan WJ, Porrata LF, Holtan SG, Blood, Amer Soc Hematology, 1/1/2011
• Maternal Systemic Immune Networks During Mid-Gestation
  Creedon D, Nevala W, Leontovich A, Markovic S, Holtan SG, Placenta, 1/1/2011
• Pneumocystis pneumonia in patients with lymphoma: Who should receive prophylaxis?
  Solomon B, Holtan SG, Letendre L, J Clin Oncol, 1/1/2010
• Using Fetomaternal Interactions To Identify Immunomodulatory Mechanisms In Melanoma
  Holtan SG, Mansfield A, Creedon D, Nevala W, Leontovich A, Markovic S, Placenta, 1/1/2010
• Immunomodulatory gene expression at the fetomaternal interface and in melanoma: Tolerance meets inflammation
  Holtan SG, Creedon D, Leontovich A, Markovic S, J Clin Oncol, 1/1/2010
• CD34+ Cell Dose and Full Donor Chimerism at Day+ 100 Is Associated with Survival in Patients Who Received Reduced-Intensity Conditioning (RIC) With Fludarabine/Melphal...
  Holtan SG, Hogan W, Elliott M, Gastineau D, Call T, Ansell S, Inwards D, Johnston P, Lacy M, Micallef I, Biology of Blood and Marrow Transplantation, 1/1/2009
• Food-Frequency Questionnaire (FFQ) Based Estimates of Total Antioxidant Capacity and Risk of Non-Hodgkin Lymphoma (NHL)
  Cerhan J, Holtan SG, O'Connor H, Fredericksen Z, Liebow M, Macon W, Wang A, Slager S, Habermann T, Call T, Cancer Ipidemiology Biomakers & Prevention, Amer Assoc Cancer Research, 1/1/2009
• Low Absolute Lymphocyte Count (ALC) at Diagnosis Is An IPSS-Independent Predictor of Poorer Survival in Myelodysplastic Syndromes (MDS)
  Jacobs NL, Holtan SG, Porrata LF, Markovic SN, Tefferi A, Steensma DP, Blood, Amer Soc Hematology, 1/1/2008
• Higher Intakes of Vegetables, Vitamin E, Manganese and Zinc Are Associated with a Lower Risk of Non-Hodgkin Lymphoma (NHL): Results from a Case-Control Study
  Holtan SG, Call TG, Fredericksen ZS, O'Connor HM, Liebow M, Macon WR, Kay NE, Micallef IN, Wang AH, Slager SL, Blood, Amer Soc Hematology, 1/1/2008
• Gemcitabine (G) and irinotecan (CPT-11) as first-line therapy for carcinoma (ca) of unknown primary (CUP): An NCCTG phase II trial
  Holtan SG, Foster N, Erlichman C, Aubry M, Ames M, Safgren S, Steen P, Morton R, Graham D, Goetz M, J Clin Oncol, 1/1/2008
• Deletion 5q in AML: A Clinicopathological Description of 79 Cases from a Single Institution
  Santana-Davila R, Holtan SG, Ketterling R, Knudson RA, Steensma DP, Chen D, Hoyer J, Hanson CA, Tefferi A, Blood, Amer Soc Hematology, 1/1/2008
• Deletion 5q in WHO-Defined Myeloproliferative Neoplasms: A Clinicopathological Description
  Santana-Davila R, Tefferi A, Holtan SG, Ketterling R, Knudson R, Steensma D, Chen D, Hoyer J, Hanson C, Blood, 1/1/2007
• Effect of AMD3100 on T Lymphocyte Subpopulations in Apheresis Products of Patients Undergoing Autologous Hematopoietic Stem Cell Transplantation for Non Hodgkin Lymphoma
  Holtan SG, Porrata LF, Inwards DJ, Ansell SA, Padley DJ, Micallef IN, Litzow MR, Johnston PB, Hayman SR, Kumar SK, Blood, 1/1/2005
• Join now to see all

Lectures

• The Evolving Treatment Landscape for Patients with GvHD: More Options, More Decisions, Better Outcomes! 
  61st Annual American Society of Hematology Meeting - Orlando, FL - 12/7/2019
• Making Progress in Graft-Versus-Host Disease Prophylaxis and Microbiome Analysis in the Blood and Marrow Transplant Clinical Trials Network: Progress III (1703)/MI-Imm... 
  61st Annual American Society of Hematology Meeting - Orlando, FL - 12/7/2019
• Facilitating Resolution of Life-Threatening Acute Graft-Versus-Host Disease By Supplementation of Human Chorionic Gonadotropin and Epidermal Growth Factor (Pregnyl): A... 
  2018 ASH Annual Meeting - San Diego, CA - 12/1/2018
• Validation of Minnesota Acute Gvhd Risk Score and Identification of New Factors Associated with Initial Response to Steroids: Not All Gvhd Is Created Equal 
  2018 ASH Annual Meeting - San Diego, CA - 12/1/2018
• Advancing Care for Patients With GvHD: Making Sense of Recent Approvals and Late-Stage Compounds 
  60th American Society of Hematology Annual Meeting - 11/30/2018
• Prognostic Impact of Follistatin in Acute Graft Versus Host Disease: Results from BMT CTN 0302 and 0802 
  San Diego, CA - 1/1/2015
• What predicts Success for a New Composite Endpoint: Graft-versus-Host Disease-Free and Relapse-Free Survival (GRFS) After Allogeneic Hematopoietic Cell Transplantation? 
  San Francisco, CA - 1/1/2014
• Chemotherapy 101 and Chemotherapy Emergencies 
  1/1/2009
• Taxol/carboplatin as salvage therapy for stage IV melanoma 
  Rochester, MN - 1/1/2005
• How Happy and Healthy are Physicians and Medical Students 
  Los Angeles, CA - 1/1/2001
• BMT: Supportive Care and Early Complications 
  University of Minnesota - 1/19/2014
• Coping with the Late and Long Term Side Effects of Stem Cell Transplants 
  Portland, OR - 1/20/2013
• Management of Allogeneic Transplant Patients 
  Portland, OR - 1/12/2013
• Inflammation and tolerance: Similarities in pregnancy and melanoma 
  1/24/2009
• Fetomaternal tolerance: Implications for novel immune-based cancer therapeutics 
  1/14/2009
• Pregnancy and Cancer: Intriguing Parallels 
  Rochester, MN - 1/22/2009
• Pregnancy and Cancer 
  1/22/2010
• Join now to see all

Other

• Cancer of Unknown Primary Site 
  Holtan SG, Enterprise Learning System, AskMayoExpert article, Mayo Clinic
  1/1/2009